NEWBORN SCREENING OF INFANTS AND NEWBORNS WITH CONGENITAL HYPOTHYROIDISM
Associate Professor Michelle Jack
Clinical Practice & Co-Lead Doctor of Medicine
Bond University, Queensland, Australia
RESEARCHER PROFILE
Filmed in Robina, Queensland | July 2024
Michelle Jack is Associate Professor of Clinical Practice, Faculty of Health Sciences & Medicine at Bond University, QLD and co-Head of Paediatrics and a Paediatric Endocrinologist at Lismore Base Hospital in NSW. She graduated from Medicine at the University of Queensland with first class honours and the University Gold Medal and has a PhD in hyperinsulinism from the University of QLD. She has postgraduate qualifications in higher education and is a fellow of the higher education academy.
Assoc Prof Jack is an experienced leader and practitioner in the healthcare, research and higher education sectors. Career highlights include: Head of Department Paediatric Endocrinology, Royal North Shore Hospital; Academic Lead Education & Partnerships, University Centre for Rural Health, University of Sydney; Head of the Beta Cell Laboratory, Kolling Institute; Chair Australasian Paediatric Endocrine Group scientific program organising committee and Co-Chair international scientific program organising committees; Chair Northern Sydney Adolescent Committee; International Research Fellowship, Juvenile Diabetes Research Foundation, Head of Research, Impact Institute.
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
